FDA Rejects Petitions Over Lost Drug Exclusivity
The U.S. Food and Drug Administration in a letter released Thursday rejected petitions from Eisai Inc. and UCB Inc. over marketing exclusivity lost because of delayed controlled-substance scheduling, saying the clock...To view the full article, register now.
Already a subscriber? Click here to view full article